GA-ASI Announces YFQ-42A Dark Merlin 
Triple Explosion: Spring Festival Gala, Livestreaming, and Offline Presence Trigger Value Realization for Shoucheng Holdings 
GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B 
GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise 
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate’s Ability to Block H5N1 Bird Flu Virus ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline data from Phase…
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
– ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis –– Commercial launch…
Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results
AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…
Trevi Therapeutics to Report Q4 and Year End 2020 Financial Results on March 25
Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn., March…
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq:…
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
– Objective Response Rate Endpoint Not Met – EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE)…
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results
Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m….
Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in…
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company…
BioRestorative Therapies Announces Filing of 2019 Annual Report on Form 10-K
MELVILLE, N.Y., March 18, 2021 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”)…
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage…
Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day
Wide-ranging transformation program completed R&D Day scheduled for April 28, 2021, to provide data updates,…
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a…
AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
-AGTC will highlight the value of the patient voice in gene therapy development- GAINESVILLE, Fla….
Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN…
Segra International Announces Development and Validation of In-House Assay for Hop Latent Viroid (HLVd)
VANCOUVER, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) — Segra International Corp, a leading cannabis…
Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently…
Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo
ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over…
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with…